Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Rating of “Hold” by Analysts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given a consensus rating of “Hold” by the five brokerages that are presently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $3.33.

Separately, StockNews.com assumed coverage on shares of Syros Pharmaceuticals in a report on Friday. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter worth about $25,000. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth about $34,000. Finally, Exome Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the period. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Trading Down 41.4 %

Syros Pharmaceuticals stock opened at $0.06 on Tuesday. The company has a market capitalization of $1.65 million, a P/E ratio of -0.02 and a beta of 1.31. The firm’s fifty day simple moving average is $0.16 and its 200-day simple moving average is $0.85. Syros Pharmaceuticals has a 1-year low of $0.06 and a 1-year high of $6.93.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.